MedTrace Logo

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

NCT05149170 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-12-08

No results posted yet for this study

Summary

The current study is a phase II multi-center single arm trial to evaluate the efficacy and safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in early-stage low-risk extranodal NK/T cell lymphoma, nasal type

Conditions

  • Early-stage
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

Interventions

DRUG

Anti-PD-1 monoclonal antibody

inductive Anti-PD-1 antibody + concurrent Anti-PD-1 antibody with RT

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • The First Hospital of Jilin University

    collaborator OTHER

  • Affiliated Cancer Hospital & Institute of Guangzhou Medical University

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Ye-Xiong Li, MD · CAMS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05149170 on ClinicalTrials.gov